Design, synthesis, in vitro evaluation, and molecular modeling studies of N‐substituted benzomorphans, analogs of LP2, as novel MOR ligands

Abstract

Abstract6,7‐Benzomorphans have been investigated in medicinal chemistry for developing new drugs. This nucleus could be considered a versatile scaffold. The physicochemical properties of benzomorphan N‐substituent are crucial in achieving a definite pharmacological profile at opioid receptors. Thus, the dual‐target MOR/DOR ligands LP1 and LP2 were obtained through N‐substituent modifications. Specifically, LP2, bearing as N‐substituent the (2R/S)‐2‐methoxy‐2‐ phenylethyl group, is a dual‐target MOR/DOR agonist and is successful in animal models of inflammatory and neuropathic pain. To obtain new opioid ligands, we focused on the design and synthesis of LP2 analogs. First, the 2‐methoxyl group of LP2 was replaced by an ester or acid functional group. Then, spacers of different lengths were introduced at N‐substituent. In‐vitro, their affinity profile versus opioid receptors has been performed through competition binding assays. Molecular modeling studies were conducted to deeply analyze the binding mode and the interactions between the new ligands and all opioid receptors.